Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 28-week Trial
Conditions
Interventions
Liraglutide
placebo
Locations
1
China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Start Date
May 9, 2020
Primary Completion Date
June 1, 2022
Completion Date
June 1, 2022
Last Updated
July 27, 2020
NCT07472881
NCT01143454
NCT07010757
NCT06989203
NCT06223555
NCT07237750
Lead Sponsor
Xiangya Hospital of Central South University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions